Johnson & Johnson (JNJ) Pushes Higher on Solid Results; Stock Moves Above 200 Day MA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Leerink Partners Raises Price Target on Johnson & Johnson (JNJ) Following 4Q Earnings
January 27, 2016 7:31 AM ESTLeerink Partners reiterated an Outperform rating on Johnson & Johnson (NYSE: JNJ), and raised the price target to $120.00 (from $115.00), following the company's 4Q earnings report. JNJ's 2015 EPS benefitted meaningfully from higher other income tied to divestitures. 2016 EPS estimate moves to $6.50 (+5%) from $6.40 previously, with better operating leverage and lower share count through buybacks offsetting ramping FX headwinds.
Analyst Danielle Antalffy... More
J&J profit beats forecasts, helped by lower taxes, cost cuts
January 26, 2016 6:51 AM ESTBy Ransdell Pierson
(Reuters) - Johnson & Johnson (NYSE: JNJ) on Tuesday reported higher-than-expected quarterly earnings, helped by cost cuts and lower taxes, and gave a 2016 profit outlook slightly above Wall Street's.
Shares of the diversified healthcare company rose almost 5 percent to $101.18 as investors shrugged off fourth-quarter sales and a 2016 revenue outlook that were both below analysts' estimates.
Edward Jones analyst Ashtyn Evans said investors were cheered by J&J's vow to make more of its medical devices market leaders and to launch 30 new devices this year, including a new insulin pump.
... MoreJohnson & Johnson (JNJ) Tops Q4 EPS by 2c
January 26, 2016 6:41 AM ESTJohnson & Johnson (NYSE: JNJ) reported Q4 EPS of $1.44, $0.02 better than the analyst estimate of $1.42. Revenue for the quarter came in at $17.8 billion versus the consensus estimate of $17.88 billion.
"Johnson & Johnson delivered strong underlying growth in 2015, driven by the performance of our Pharmaceutical business and iconic Consumer brands," said Alex Gorsky, Chairman and Chief Executive Officer. "As we enter 2016, our core business is very healthy, and the recent decisive actions we've taken in support of each of our businesses position us well to drive sustainable long-term growth, faster than the markets we... More
